GE HealthCare has launched the Invenia Automated Breast Ultrasound (ABUS) Premium, an advanced 3D ultrasound system designed to improve cancer detection in dense breast tissue. Studies show that dense breasts increase the risk of undetected cancers, as mammograms may not always provide clear results. ABUS technology has been shown to improve sensitivity in detecting invasive cancer when used alongside mammography. The Invenia ABUS Premium integrates AI to enhance image quality, improve scan efficiency, and assist in identifying potential abnormalities. It features tools including Scan Quality Assessment for real-time image evaluation and Auto Nipple Detection for consistent positioning. The Fast Scan tool increases scanning speed by up to 40 percent, while cSound Imageformer ensures high-resolution imaging.
The AI-powered Invenia ABUS Viewer allows physicians to review and interpret 3D breast scans remotely, improving workflow efficiency and addressing staffing shortages. The non-invasive design enhances patient comfort, with a recent study reporting that all participants would recommend the exam to others. The system also reduces unnecessary biopsies by distinguishing between benign and malignant tumors. Invenia ABUS Premium, which has been approved by the FDA, will be available in important countries in 2025. It has also been featured at major radiology conferences, emphasizing its role in increasing breast cancer diagnosis.
